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Background: Random glucose is widely measured in epidemiological studies and in the clinical setting when
standardized fasting protocols and oral glucose tolerance testing or HbA1c measuring are not feasible. The
relationship between random glucose and all-cause mortality has hardly been studied so far and was examined in
the present study.
Methods: We ascertained mortality status among 5955 persons aged 18–79 years and free of known diabetes
when participating in the German National Health Interview and Examination Survey 1998 (mean observation time
11.7 years, 458 deaths). Cox regression was applied to analyze the association of random serum glucose with all-
cause mortality taken potential confounders into account. Relative mortality risks were estimated as hazard ratios
(HRs) with 95% confidence intervals (CIs) modeling random glucose as categorical or continuous variable.
Results: Compared to random glucose levels of 4.3 - < 5.3 mmol/L, HRs (95% CIs) were 1.94 (0.85–4.45) for levels
< 4.3 mmol/L and 1.16 (0.89–1.50), 1.20 (0.91–1.58), 1.42 (0.88–2.29), 2.02 (1.26–3.25) and 4.71 (2.20–10.10) for levels
5.3 - < 5.8, 5.8 - < 6.8, 6.8 - < 7.8, 7.8 - < 11.1 and ≥ 11.1 mmol/L, adjusted for age, sex, lifestyle, anthropometry and
chronic diseases. An additional adjustment for fasting time or HbA1c yielded similar estimates. Modeling continuous
random glucose by restricted cubic spline functions revealed comparable findings.
Conclusions: In the present epidemiological study drawn from the general population, random glucose showed a
significant association with all-cause mortality, independent of main potential confounders. Thus, random glucose
measures are highly relevant to health risk assessment among people without known diabetes when fasting
glucose or HbA1c are difficult to obtain.
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Diabetes and preceding states of hyperglycemia are
major risk factors for cardiovascular disease (CVD) and
mortality and highly prevalent among adults in Germany
and worldwide [1–4]. However, findings on mortality
risk vary according to the glycemic measure applied, as
shown in a recent systematic review including a
meta-analysis of 25 prospective studies among persons
with prediabetes [5]. Numerous studies found strong in-
creases in CVD mortality risk for elevated fasting glu-
cose levels [2, 6, 7]. Studies investigating the association
between HbA1c and mortality risk among people without
diagnosed diabetes have reported conflicting results,
with most studies showing a J shaped association with
increased risk at very low HbA1c measures as well as at
measures at 6.4% or above [8, 9].
Fasting glucose and HbA1c are routine measures for gly-
cemic status used for diagnosing diabetes; however, there is
evidence that applying currently recommended diagnostic
criteria for the diagnosis of previously unknown diabetes or
prediabetes using fasting glucose and HbA1c are not identi-
fying the same people [10]. Furthermore, fasting glucose is
rather difficult to obtain in large epidemiological studies
and sometimes even in daily routine care, because individ-
uals are often not in a fasting state at blood withdrawal.
Moreover, different definitions for the fasting state are in
use, especially in terms of fasting time, which may contrib-
ute to inconsistent glucose measurements and findings
across studies [11]. HbA1c assessment is connected with
higher costs compared to glucose measurement.
Against this background, we examined whether ran-
dom glucose as a less well-standardized but highly feas-
ible measure is predictive of mortality from all causes
among people without previously diagnosed diabetes.
While it is well-known that random glucose is a strong
predictor of incident diabetes [12, 13], the relationship
to mortality has hardly been studied so far and did not
include all-cause mortality as an outcome [14, 15].
Therefore, we asked: (1) Is there a significant relation-
ship independent of potential confounders? and (2) Do
fasting time and HbA1c contribute to explain the rela-
tionship between random glucose and mortality?
Methods
Study design and setting
The present analysis is based on the mortality follow-up
of the German National Health Interview and Examin-
ation Survey 1998 (GNHIES98) sample. The GNHIES98
was conducted by the Robert Koch Institute between
October 1997 and March 1999 and included 7124 adults
representative of the 18 to 79-year-old residential,
non-institutionalized population in Germany. Details of
the study design, sampling procedure, response rates
and data collection have been published previously [16].In brief, a two-stage cluster sampling procedure was ap-
plied for the selection of survey participants (response
rate: 61.4%). In the first stage of sampling, sample points
(i.e. study locations) reflecting community sizes and
structures in Germany were drawn and in the second
stage, random samples stratified by sex and age were se-
lected from local population registries proportional to
the sex and age structure of the population in Germany.
The survey included a standardized computer-assisted
personal interview (CAPI) administered by specifically
trained study physicians, a standardized self-administered
questionnaire which was checked by trained interviewers
for plausibility and completeness, and a physical examin-
ation, including standardized anthropometric measure-
ments and blood sampling as well as a detailed
medication review conducted by trained health profes-
sionals. Blood samples were drawn over the day and proc-
essed within one hour and stored at − 40 °C until analysis
in the central laboratory unit at the Robert Koch Institute.
Any medications taken in the past 7 days were recorded
using the unique medication identifiers (“Pharmazentral-
nummer”, PZN) on the original medication containers
brought to the study center by study participants for this
purpose. The PZN was used for medication coding ac-
cording to the WHO “Anatomical-Therapeutic-Chemical”
classification system (ATC-Code).
The vital status could be assessed for 6979 among the
7124 GNHIES98 participants (98.0%) by the mortality
follow-up as previously described in detail [17]. Briefly,
all GNHIES98 participants who had agreed to follow-up
contacts were recontacted between October 2008 and
October 2011 and invited to participate in the first wave
of the German Health Interview and Examination Sur-
vey for Adults (DEGS1). For participants who did not re-
spond to the invitation, vital status was obtained from
local population registries including the date of death for
deceased individuals. Surviving GNHIES98 participants
were censored at the last date of contact, i. e. the date of
contact to the population registry for non-respondents,
the date of refusal for those who actively declined par-
ticipation in DEGS1, or the date of DEGS1 participation
for those who also took part in DEGS1.
The GNHIES98 and its mortality follow-up were ap-
proved by the Federal Office for the Protection of Data
(Germany). All participants provided written informed
consent before enrolment.
Study population
Among 7124 participants of the GNHIES98 study, a
number of 6750 individuals reporting no history of
physician-diagnosed diabetes and no use of antidiabetic
medication within the last seven days preceding the
interview were defined as free of known diabetes at the
baseline examination and comprised the source
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sion of participants with no information regarding vital
status (n = 138), known diabetes (n = 25), random glu-
cose level or fasting time (n = 336) or main covariates
used in the present analyses (n = 299), the final study
population consisted of 5955 participants (2919 men
and 3036 women) aged 18–79 years at baseline.Assessment of random glucose and fasting time
Random glucose was determined by standardized mea-
sures of serum glucose drawn from fresh whole blood
specimens randomly taken over the day using
glukose-oxidase-peroxidase-4-aminophenazon-phenol by
a MEGA analyzer (Merck, Darmstadt, Germany). For ana-
lyses as categorical variable, random glucose level was
classified in seven categories (< 4.3, 4.3 - < 5.3, 5.3 - < 5.8,
5.8 - < 6.8, 6.8 - < 7.8, 7.8 - < 11.1 and ≥ 11.1mmol/L) as
previously suggested [14]. The two highest categories
followed classifications concerning oral glucose tolerance
2-h postload thresholds for assessing diabetes and im-
paired glucose tolerance [4].
Fasting time was defined as the difference between
time of drawing blood specimen and time since the last
meal was taken, the latter based on self-report. For
specific analyses, fasting time was classified into the cat-
egories < 2, 2 - < 4, 4 - < 8, 8 - < 12 and ≥ 12 h.Assessment of covariates
Covariates were chosen a priori to control for potential
confounding of the relationship between random glucose
and all-cause mortality. Age, sex, educational level,
smoking status, alcohol intake and physical activity were
obtained by self-administered questionnaire, anthropo-
metric measures by physical examination, history of
chronic diseases by CAPI and HbA1c by blood sampling.
Educational level was assessed by the Comparative
Analysis of Social Mobility in Industrial Nations (CAS-
MIN) instrument, encompassing general as well as voca-
tional training, and classified into the categories low,
medium or high [18].
Smoking status was categorized as never, former and
current smoking. Alcohol intake (g/day) was obtained by
a semi-quantitative food frequency questionnaire [19]
and classified into no, moderate (> 0 - < 20 g/day in men,
> 0 - < 10 g/day in women) and high (≥ 20 g/day in men,
≥ 10 g/day in women) alcohol intake. Physical activity
was assessed by five categories as no sport, < 1 h/week,
regularly 1–2 h/week, regularly 2–4 h/week, or regularly
> 4 h/week. This information was aggregated into two
categories (< 2 h/week or ≥ 2 h/week) for the present
analysis. Body mass index (BMI) was calculated as the
ratio of body weight (kg) and height squared (m2). History
of myocardial infarction, stroke, cancer, hypertension andhyperlipidemia were chosen as chronic diseases and were
each defined as no or yes.
HbA1c was measured in fresh whole blood specimens
with a Diamat high-performance liquid chromatography
analyzer (Bio-Rad Laboratories, Munich, Germany) and
reagents of Recipe (Recipe Chemicals and Instruments,
Munich, Germany) in the Robert Koch Institute Central
Epidemiological Laboratory [20]. For specific analyses,
HbA1c level was classified into < 5.0, 5.0 - < 5.7, 5.7
- < 6.5 and ≥ 6.5% as previous studies showed a U form
relation of HbA1c and all-cause mortality [8, 21].
Statistical analyses
Unadjusted analyses were performed by the Rao-Scott χ2
test for associations between random glucose categories
and categorical variables and by the F test for mean
differences for continuous and (approximately) normally
distributed variables across random glucose categories.
Spearman correlation was applied to assess a potential
monotonic relationship between continuous random glu-
cose and fasting time. To display distribution measures of
continuous random glucose across five fasting time cat-
egories, a Box plot was created. Crude mortality rates
were calculated by dividing the number of deaths by the
number of person-years observed within each random
glucose category.
Adjusted analyses were performed by Cox proportional
hazards regression models to estimate random
glucose-specific hazard ratios (HRs) including 95% confi-
dence intervals (95% CIs) for all-cause mortality during
follow-up. As basic model, model 1 was adjusted for age
(continuous) and sex. Further adjustments were made for
the sociodemographic factor educational level in model 2,
additionally for the lifestyle factors smoking, alcohol
consumption and physical activity as well as the anthropo-
metric factors BMI (continuous) and waist circumference
(continuous) in model 3, and additionally for the five
chronic diseases history of myocardial infarction, stroke,
cancer, hypertension and hyperlipidemia in model 4.
First, random glucose was included in the Cox regres-
sion models as categorical variable using a level of 4.3
- < 5.3 mmol/L as reference. Secondly, random glucose
was included as continuous variable in the Cox regression
and modelled by a spline regression approach applying
restricted cubic spline functions with four knots set at the
5th, 25th, 75th and 95th percentile and choosing the
median random glucose level of 5.2 mmol/L as reference.
Sensitivity analyses were performed to assess the
stability of the main analyses and comprised a) an
additional adjustment for fasting time (< 2, 2 - < 4, 4 - < 8,
8 - < 12, ≥ 12 h), b) an exclusion of participants with
fasting time < 2 h, c) an additional adjustment for HbA1c
(< 5.0, 5.0 - < 5.7, 5.7 - < 6.5 and ≥ 6.5%), d) an exclusion of
participants with HbA1c ≥ 6.5%, e) an exclusion of
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analysis in the source population (n = 6750) with multiple
imputation of missing values using the “Fully Conditional
Specification” method [22]. Furthermore, interaction ana-
lyses were carried out to examine potential modifications
of the random glucose-mortality association by age, BMI
and waist circumference (all continuous) and sex with add-
ing the respective interaction terms (random glucose x
modifier) to the Cox regression model 4 (described above).
Statistical analyses were performed by the statistical soft-
ware package SAS version 9.4 (SAS Institute, Cary, NC,
USA) using the survey procedures SURVEYMEANS,
SURVEYFREQ and SURVEYPHREG to account for the
complex survey design, except for analyses regarding
Spearman correlation and spline modelling in the Cox
regression (see below). The analyses included a survey
weight accounting for deviations of the study population
from the population in Germany as of December 31, 1997
within strata of sex, age, education, nationality, community
size, federal state, and east/west Germany which may
compensate under- or over-represented groups within
these strata. Spearman correlation analyses were un-
weighted using CORR and spline modelling in the Cox
regression was performed by PHREG which permitted
consideration of weights but not accounting for cluster
sampling. P values < 0.05 were considered to indicate
statistical significance. The study followed the STROBE
guidelines for cohort studies [23].
Results
Description of study population
Random glucose had a median level of 5.2mmol/L and
ranged from 2.6 to 20.6mmol/L. Table 1 shows the distribu-
tion of baseline characteristics across seven random glucose
categories. Participants with higher random glucose categor-
ies were significantly more often older, male, low educated,
obese, current smokers, high alcohol consumers, physically
inactive and reported more often a history of myocardial in-
farction, stroke, hypertension and hyperlipidemia compared
to participants with lower random glucose categories.
Association of random glucose and fasting time
Median fasting time was 5.4 h with lower quartile 3.8 h
and upper quartile 8.6 h. Continuous random glucose level
and fasting time were weakly and non-monotonically
correlated (Spearman’s ρ = − 0.044) as shown by a scatter
plot (Fig. 1).
A Box plot revealed comparable distribution measures
for random glucose levels across five fasting time cat-
egories (Additional file 1: Figure S1); slightly higher
=median random glucose (5.4 mmol/L) and higher vari-
ation in glucose measures was observed among persons
with lowest fasting time (< 2 h) as compared to those
with fasting times between 2- < 4 h and ≥ 12 h.Association of random glucose and all-cause mortality
A total number of 458 deaths (men: 287, women: 171)
was observed over a mean follow-up time of 11.7 years
(standard error 0.1). Crude mortality rates per 1000
person-years ranged from 3.8 in the lowest to 41.2 in the
highest random glucose category (Table 2).
Compared to participants with random glucose levels
in the reference category (4.3 - < 5.3 mmol/L), the age-
and sex-adjusted relative mortality risk estimated by Cox
regression was significantly increased for participants in
the lowest random glucose category (< 4.3 mmol/L) as
well as for those with random glucose levels in the two
highest categories (model 1, Table 1) which persisted
after further adjustment for educational level, lifestyle
and anthropometry (model 3). Additional adjustment
for major chronic diseases attenuated the relative mor-
tality risk (HR: 1.94, 95% CI: 0.85–4.45) for participants
in the lowest random glucose category to non-significance,
but not for those in the higher categories with HRs
(95% CI) of 1.16 (0.89–1.50), 1.20 (0.91–1.58), 1.42
(0.88–2.29), 2.02 (1.26–3.25) and 4.71 (2.20–10.10) for
levels of 5.3 - < 5.8 to ≥11.1 mmol/L (model 4).
Modeling continuous random glucose levels by restricted
cubic spline functions in the Cox regression models
revealed a similar shape of the random glucose-mortality
association as shown for model 4 (Fig. 2). However, the
confidence intervals at the tails of the hazard ratios were
wide due to the low number of participants with extreme
random glucose values.
Sensitivity analyses
Additional adjustment for fasting time in model 4 or ex-
cluding participants with fasting time < 2 h did not
change estimates substantially (Table 3a and b). Hazard
ratios for the two highest categories were attenuated but
remained significantly increased when additionally
controlling for HbA1c (Table 3c). After excluding par-
ticipants with HbA1c ≥ 6.5%, no more observations in
the highest random glucose category were observed;
however, the relative risk of death was significantly
increased among persons with random glucose levels
of 7.8 - < 11.1 mmol/L (Table 3d). Comparable estimates
as in the main analyses were obtained when participants
with follow-up time ≤ 2 years were excluded (Table 3e).
Performing the main analyses in the source population
(n = 6750) with imputation of missing variable informa-
tion estimated significant hazard ratios for the three high-
est categories; the hazard ratio for random glucose
level ≥ 11.1 mmol/L was lower than in the analyses using
the study population (2.96 versus 4.71) (Table 3f).
Interaction analyses
No significant modifications in the association of random
glucose level category and all-cause mortality was
Table 1 Baseline characteristics of the study population by random glucose categories
Random glucose category (in mmol/L)
Characteristic < 4.3 4.3 - < 5.3 5.3 - < 5.8 5.8 - < 6.8 6.8 - < 7.8 7.8 - < 11.1 ≥ 11.1 p value
N 224 3,105 1,510 843 161 93 19 -
Age class (%) < 0.001
18-39 years 74.6 52.2 34.9 23.7 26.3 14.4 11.8
40-49 years 15.2 19.9 18.5 18.7 10.6 14.0 21.8
50-59 years 6.5 14.4 20.1 19.9 27.9 23.3 25.1
60-69 years 2.2 9.1 15.4 24.1 21.1 28.3 23.8
70-79 years 1.5 4.5 11.0 13.6 14.1 20.0 17.5
Age (years) 33.4 (1.1) 41.1 (0.4) 48.0 (0.6) 51.9 (0.7) 52.1 (1.6) 57.4 (1.8) 56.5 (2.7) < 0.001
Male sex (%) 42.6 45.3 54.0 59.3 60.6 60.2 56.9 < 0.001
Educational level (%) < 0.001
Low 42.8 43.3 50.8 58.2 55.6 62.8 72.7
Medium 42.8 44.3 36.6 30.1 35.0 30.9 16.3
High 14.5 12.4 12.6 11.7 9.4 6.3 11.0
BMI category (%)2 < 0.001a
< 25 kg/m 64.1 47.5 34.2 26.2 17.7 19.3 n.a.a
25- < 30 kg/m2 28.9 36.2 43.5 45.7 50.4 29.1 35.7
≥ 30 kg/m2 6.9 16.2 22.3 28.1 31.9 51.5 64.3
BMI (kg/m2) 24.1 (0.3) 25.9 (0.1) 27.1 (0.1) 27.9 (0.2) 28.7 (0.4) 30.5 (0.7) 32.6 (1.4) < 0.001
Waist circumference category (%)b < 0.001
Normal 65.6 50.5 35.5 27.9 22.3 17.0 2.5
Moderate 22.6 24.1 27.1 26.7 27.5 21.3 10.0
High 11.9 25.4 37.4 45.4 50.2 61.6 87.5
Waist circumference (cm)c
Men 88.9 (1.1) 94.4 (0.4) 96.7 (0.4) 99.1 (0.6) 100.1 (1.8) 102.0 (1.5) 109.8 (3.2) < 0.001
Women 78.4 (1.1) 81.8 (0.4) 86.8 (0.6) 90.0 (0.8) 91.5 (1.8) 99.4 (2.4) 105.9 (3.4) < 0.001
Smoking (%) < 0.001
Never smoker 48.3 36.9 30.4 28.7 27.4 24.9 30.3
Former smoker 12.9 19.4 23.4 25.7 27.5 23.9 20.0
Current smoker 38.8 43.7 46.2 45.7 45.1 51.2 49.7
Alcohol consumption (%)d < 0.001
No 21.7 18.4 18.2 18.2 16.5 27.9 9.0
Moderate 69.8 63.9 59.2 59.7 57.7 49.9 52.4
High 8.5 17.7 22.6 22.1 25.7 22.2 38.6
Physical activity < 2 h/week (%) 72.8 78.9 80.9 83.3 84.6 88.2 96.5 0.003
History of chronic diseases
Myocardial infarction 0.6 1.2 1.6 3.6 5.2 3.6 3.7 < 0.001
Stroke 0.4 0.6 1.2 1.0 0.6 6.4 4.0 < 0.001
Cancer 2.5 2.8 3.2 3.6 3.5 5.7 4.0 0.682
Hypertension 4.9 14.6 24.2 32.6 35.6 54.0 48.7 < 0.001
Hyperlipidemia 8.5 17.9 25.7 28.8 33.2 38.6 55.5 < 0.001
Information is given as arithmetic mean (standard error) or percentage. Differences in means or percentages by random glucose categories were assessed by
F test or Rao-Scott χ2 test
a no observations in this cell; p value for association excluding random glucose level ≥ 11.1 mmol/L
b normal / moderate / high: < 94 / 94 - < 102 / ≥ 102 cm in men and < 80 / 80 - < 88 / ≥ 88 cm in women
c mean (standard error) is given separately for men and women due to sex-specific differences in waist circumference distribution
d no / moderate / high: 0 / > 0 - < 20 / ≥ 20 g/day in men and 0 / > 0 - < 10 / ≥ 10 g/day in women
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Fig. 1 Correlation of random glucose and fasting time, displayed as scatter plot
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for interactions 0.208, 0.744 and 0.108). However, a signifi-
cant interaction was estimated regarding waist circumfer-
ence (p for interaction 0.011); the association was more
pronounced in participants with higher than with lower
waist circumference levels. Modelling random glucose
level by restricted cubic spline functions revealed no sig-
nificant interaction by age, sex, BMI or waist circumfer-
ence (p for interactions 0.133, 0.156, 0.802 and 0.410).
Discussion
Overall findings
In the present epidemiological study drawn from the
general population, random glucose was significantly as-
sociated with all-cause mortality, as an increase in mor-
tality risk was found in participants with very low andTable 2 Mortality rate and risk for all-cause mortality (HR (95% CI)) b
Random glucose category (in mmol/L)
< 4.3 4.3 - < 5.3 5.3 - < 5.8 5.8 -
N 224 3105 1510 843
N of deaths 10 158 124 110
Crude MRa 3.8 4.0 8.1 11.8
Model 1 2.46 (1.12–5.38) ref. 1.06 (0.84–1.34) 1.18
Model 2 2.43 (1.11–5.34) ref. 1.06 (0.84–1.35) 1.18
Model 3 2.11 (1.00–4.43) ref. 1.14 (0.90–1.46) 1.22
Model 4 1.94 (0.85–4.45) ref. 1.16 (0.89–1.50) 1.20
a MR: crude mortality rate per 1000 person-years
model 1: adjusted for age and sex
model 2: adjusted for age, sex and educational level
model 3: adjusted for age, sex, educational level, body mass index, waist circumference
model 4: adjusted for age, sex, educational level, body mass index, waist circumference
activity, myocardial infarction, stroke, cancer, hypertension and hyperlipidemiahigh random glucose levels which was independent from
main mortality-related risk factors as well as from fast-
ing time and HbA1c. Changes in the effects of random
glucose levels on mortality risk were rather low when
adjusting for these factors. As far as we know, this is the
first investigation about the association of random glu-
cose and all-cause mortality in a study population drawn
from the general population.
Association of random glucose and all-cause mortality
The present study investigated the association of ran-
dom glucose with all-cause mortality, in contrast to a
variety of previous studies which examined other end-
points. A large study based on a population-based sam-
ple of Chinese adults found a monotonically increasing
CVD mortality risk using the same random glucosey random glucose categories




(0.93–1.51) 1.34 (0.83–2.15) 1.85 (1.15–2.98) 4.36 (2.00–9.50)
(0.93–1.51) 1.29 (0.80–2.08) 1.77 (1.08–2.90) 4.45 (2.07–9.55)
(0.94–1.59) 1.43 (0.90–2.26) 1.79 (1.07–3.01) 4.42 (2.14–9.11)
(0.91–1.58) 1.42 (0.88–2.29) 2.02 (1.26–3.25) 4.71 (2.20–10.10)
, smoking, alcohol consumption and physical activity
, smoking, alcohol consumption, physical
Fig. 2 Risk for all-cause mortality (95% CI) by continuous random glucose level, estimated by Cox regression and applying restricted cubic spline
functions for modelling random glucose level
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all-cause mortality, CVD mortality risks here were al-
most equal in the two lowest categories. Rosness et al.
studied the association of random glucose (categorical
and continuous) with dementia-related mortality in two
study populations from Norway with different age ranges
(35–49 and 65–80 years) and observed a relation in the
younger but not in the older age group [15]; random
glucose was categorized in quintiles as well as modelled
with spline functions.
Both studies above did not show a U or J shaped
association which may be due to different mortality
endpoints (CVD or dementia-related in contrast to
all-causes). However, in a large collaborative investiga-
tion including 48 studies with about 33,000 cases ofTable 3 Sensitivity analyses for risk for all-cause mortality (HR (95% C
Random glucose category (in mmol/L)
Model < 4.3 4.3 - < 5.3 5.3 - < 5.8
a) adjusted for fasting timea 1.96 (0.87–4.43) ref. 1.16 (0.89–1.5
b) excluding fasting time < 2 hb 2.07 (0.85–5.03) ref. 1.14 (0.87–1.5
c) adjusted for HbA1c
c 1.96 (0.86–4.44) ref. 1.17 (0.90–1.5
d) excluding HbA1c≥ 6.5%
d 1.73 (0.73–4.09) ref. 1.12 (0.85–1.4
e) excluding FU time ≤ 2 yearse 2.10 (0.87–5.06) ref. 1.12 (0.85–1.4
f) multiple imputationf 1.68 (0.92–3.07) ref. 1.12 (0.88–1.4
Models with adjustment as in model 4 with additional adjustment for fasting time in a
a fasting time with five categories (< 2, 2 - < 4, 4 - < 8, 8 - < 12 and ≥ 12 h)
b n = 5579 (428 cases, 5151 non-cases)
c HbA1c with five categories (< 5.0, 5.0- < 5.7, 5.7- < 6.5, ≥ 6.5%)
d n = 5718 (386 cases, 5332 non-cases), no participant with random glucose ≥ 11.1 mm
e n = 5912 (415 cases, 5497 non-cases)
f n = 6570 (551 cases, 6061 non-cases, 138 missings), missings were replaced in the soudeath, a J shaped association of fasting glucose and death
from all causes was reported in subjects without known
diabetes and known pre-existing cardiovascular disease
at baseline [2]. In a previous study regarding HbA1c as
another glycemic marker using the same data source
(GNHIES98) as in the present analyses, Paprott et al. re-
vealed a U shaped HbA1c-mortality relation when HbA1c
was modelled with spline functions in subjects without
known diabetes indicating that very low HbA1c levels are
associated with increased risk for all-cause mortality,
additionally to high HbA1c levels (≥ 6.4%) [8]. This is in
line with findings of a meta-analysis of observational
studies which indicated a J shaped relationship between
HbA1c levels and all-cause mortality in the non-diabetic
as well as in the diabetic population [9].I)) by random glucose categories
5.8 - < 6.8 6.8 - < 7.8 7.8 - < 11.1 ≥ 11.1
1) 1.22 (0.92–1.60) 1.46 (0.89–2.39) 2.10 (1.28–3.42) 4.99 (2.33–10.73)
0) 1.18 (0.89–1.57) 1.43 (0.85–2.41) 2.20 (1.25–3.86) 4.38 (2.01–9.58)
1) 1.21 (0.91–1.60) 1.35 (0.83–2.20) 1.82 (1.09–3.03) 3.46 (1.49–8.04)
8) 1.23 (0.92–1.63) 1.08 (0.54–2.13) 2.46 (1.50–4.03) –
6) 1.11 (0.82–1.48) 1.30 (0.77–2.19) 1.97 (1.21–3.21) 3.72 (1.51–9.19)
1) 1.25 (0.98–1.59) 1.81 (1.17–2.80) 1.94 (1.26–3.01) 2.96 (1.48–5.92)
) and HbA1c in c)
ol/L
rce population using multiple imputation by fully conditional specification
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tality was independent of main other mortality-related
risk factors. The changes in the hazard ratios when
sociodemographic and lifestyle factors as well as chronic
diseases were taken into account was rather low in the
two highest random glucose categories indicating no
substantial confounding in the effects on all-cause mor-
tality by these factors. In contrast, the effect change for
the lowest random glucose category (< 4.3 mmol/L) by
these adjustments was more pronounced especially
when chronic diseases were included in the regression
model. Thus, the increased mortality risk in the very low
compared to the reference random glucose group may
partly be explained by these unfavourable conditions as
previously found for low HbA1C levels [8]. However, as
the number of events in the lowest random glucose cat-
egory was only 10, this finding should not be overinter-
preted; larger studies are necessary to examine the
relation of very low random glucose levels and all-cause
mortality in more detail.
Our interaction analyses suggest that an increased
mortality risk in low and high random glucose levels was
more pronounced in participants with higher compared
to lower waist circumference levels. Previously, an in-
creased risk for all-cause mortality has been shown for el-
evated levels of waist circumference in a population-based
study of Canadian adults [24]. Considering this finding in
the face with our interaction analysis may indicate that
especially a combination of unfavourable levels in random
glucose (low and high) and waist circumference (elevated)
is related to an increased mortality risk which was surpris-
ing and may deserve further attention in future and larger
studies.
However, the low case numbers at both tails of the
random glucose level distribution should be kept in
mind here and therefore interpretation regarding the
interaction findings in the present study should be taken
with caution.
Random glucose and fasting time
In the present study, the correlation between random
glucose and fasting time was weak (correlation coeffi-
cient − 0.04); the distribution of random glucose was ra-
ther comparable across five fasting time categories,
however a non-monotonic and suggestive J shaped asso-
ciation could be observed as shown in Additional file 1:
Figure S1. This finding may be initially surprising as
considerable more pronounced differences would be ex-
pected. However, Moebus et al. reported mean random
glucose values of 5.3 mmol/L at zero hours, 5.2 mmol/l
at two hours and 5.0 mm/L at 8 h since last caloric in-
take in a study of about 28,000 primary care patients
[11] and that higher mean random glucose levels are
mainly seen in the first 3 h after a caloric intake which iscomparable to our findings. A study of non–glucose-
intolerant adults (i.e. also without diabetes) with existing
CVD drawn from the Framingham Heart Study (FHS)
showed only little differences in age- and sex-adjusted per-
centiles between random glucose and fasting glucose [25].
In our study, additional adjustment for fasting time did
not alter substantially the random glucose-mortality rela-
tion. Regarding other endpoints, a study from Asia and the
Pacific region had data on both random and fasting glucose
and revealed weaker estimates regarding stroke but com-
parable estimates regarding ischemic heart disease (IHD)
for random compared to fasting glucose [26].
Limitations and strengths
Our study has some limitations which are described in
the following. First, although the study population and
the overall number of fatal cases were large, the number
of cases was rather low for very low and high glucose
levels leading to wide confidence intervals; thus, findings
should be interpreted with caution for random glucose
values at the tails of the distribution. Second, random
glucose was measured in serum in contrast to several
other studies where blood plasma was used. However,
glucose values measured in serum or plasma seem to
differ only slightly with lower values in serum which
may be considered as not physiologically relevant [27].
Third, random glucose was measured only at the base-
line examination; thus potential changes in random glu-
cose levels at the individual level per participant during
the follow-up time could not be assessed. Fourth, though
non-response in our study was addressed by using survey
weights which may compensate under-represented groups
(e.g. older aged or low educated), a possible selection bias
due to non-response cannot be excluded. Fifth, about 12%
of participant had to be excluded due to missing informa-
tion in at least one of used variables which may lead also to
selection bias. However, a sensitivity analysis applying
multiple imputation revealed comparable findings as in the
main analyses indicating a rather low selection bias due to
missing information. Sixth, residual confounding cannot be
excluded, especially regarding further mortality-related risk
factors and subclinical diseases which could not be taken
into account in the present analyses.
A major strength of the present study is that it was
based on a large population-based sample representative
of the adult population in Germany with standardized
and quality controlled data ascertainment. The mortality
follow-up was almost complete with only 2% of partici-
pants lost to follow-up; furthermore, the mean follow-up
time of almost 12 years was rather long.
Conclusions
The present study conducted in a nationally representa-
tive study population indicated a significant association
Baumert et al. BMC Endocrine Disorders           (2018) 18:95 Page 9 of 10of random glucose levels with all-cause mortality in
adults without known diabetes, even after controlling for
mortality-related risk factors, HbA1c and fasting time.
Surprisingly, the correlation between random glucose
level and fasting time was non-monotonic and weak.
Undoubtedly, measuring fasting glucose or HbA1c have
the advantage of being more precise in assessing diabetes
risk and diagnosis. However, regarding the value for the
assessment of mortality risks in epidemiological studies
with large sample size, fasting glucose, HbA1c and random
glucose seem to be comparable. The advantage of random
glucose consists in its easy assessment independent of the
fasting state in contrast to fasting glucose and is con-
nected with lower costs compared to HbA1c which makes
it a suitable marker in specific situations. This is particu-
larly true for large population-based health studies, since
fasting blood sampling after an overnight fasting period
may jeopardize participation rates.
In conclusion, our findings add to existing evidence that
random glucose is a useful tool for assessing health risks
among people without diagnosed diabetes, especially
when fasting glucose or HbA1c is difficult to obtain.
Additional file
Additional file 1: Figure S1. The box plot gives information about
distribution measures of random glucose levels stratified by fasting time
categories: the full range from minimum to maximum (at bottom and
top of the whiskers), the interquartile range from lower to upper quartile
(at bottom and top of the boxes), the median (straight line inside the
boxes) and the mean (point inside the boxes); the median values in the
fasting time categories are connected by a solid line. (DOCX 30 kb)
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